

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
| Drug common name | Upamostat |
| INN | upamostat |
| Description | Upamostat (WX-671, Mesupron) is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: proteolytic enzyme inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(/C(N)=N\O)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1 |
| PDB | — |
| CAS-ID | 1191101-18-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4206119 |
| ChEBI ID | — |
| PubChem CID | 9852201 |
| DrugBank | DB13052 |
| UNII ID | S5M7KW6U17 (ChemIDplus, GSRS) |
